10/28/2026
Pharma giants invest billions in psychedelics despite hurdles
Psychedelics like MDMA and psilocybin gain traction amid regulatory challenges.
Topic archive
compass pathways
7 stories
10/21/2026
Psychedelics and Silicon Valley: A new frontier
Psychedelics shift from counterculture to tech industry darling, reshaping capitalism.
9/16/2026
Compass Pathways reports 52-week follow-up on psilocybin trial
Phase 3 trial shows potential benefits for treatment-resistant depression.
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
8/19/2026
Trump's FDA pick Overton may boost psychedelics, pain meds
Heidi Overton's nomination could advance psychedelic therapies but raises vaccine concerns.
8/8/2026
SAMHSA gathers experts on psychedelics
AtaiBeckley and Compass Pathways explore new opportunities.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.